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NPM-MLF1 synergizes with Npm haploinsufficiency to enhance myeloid progenitor activity Myelodysplastic syndromes (MDS) are defined as clonal disorders of haematopoietic stem/progenitor cells (HSPCs), characterized by ineffective haematopoiesis, peripheral blood cytopenia, morphologic dysplasia and susceptibility to acute myeloid leukemia (AML). 1, 2 Although cytogenetic abnormalities can be identified in about half the cases of MDS, 3 relatively little is known about the genetic basis of MDS. The t(3;5)(q25;q34) translocation, creating the NPM-MLF1 fusion, has been found as a sole cytogenetic abnormality in MDS/ AML patients. 4 The nucleophosmin1 (NPM1) gene, located on 5q35, encodes a protein that takes part in a diversity of biological processes such as centrosome duplication, genomic stability and ribosome biogenesis. 5 In MDS/AML patients with t(3;5), inactivation of one functional NPM allele resulting from the t(3;5)(q25;q34) translocation may be a key event in disease development. This concept is supported by the observations that Npm þ /À mice exhibit some of the disease phenotypes resembling human MDS, 6 and show predisposition to leukaemia. 7 Therefore, we postulate that in patients, reduction in the expression levels of wild-type NPM1 is essential for the induction of MDS by NPM-MLF1.
In this report, we show that wild-type NPM and NPM-MLF1 physically interact. Reducing wild-type NPM levels enabled NPM-MLF1 to enhance the colony-forming activity of myeloid HPCs during a prolonged period of liquid culture. This was accompanied by concomitant increased expression of Hoxa9/10 and Meis1 genes, an important measure of the oncogenic potential of myeloid progenitors. 8 --10 Our data demonstrate that Npm haploinsufficiency is critical for NPM-MLF1 to enhance myeloid progenitor activity, essential for the initiation of MDS.
A key feature of the NPM-MLF1 fusion gene is that it retains the homo-dimerization domain of NPM. This suggests that wild-type NPM may be capable of interaction with the NPM-MLF1 fusion protein. To test this hypothesis we performed immunoprecipitations of cell lysates from NPM-MLF1-expressing mouse NIH-3T3 fibroblasts. Total cell lysates were immunoprecipitated with an antibody against the C-terminus of NPM (a moiety not present in the NPM-MLF1 fusion) or with an IgG1-k antibody as an isotype control, and immunoblotted with FLAG antibody to detect the presence of co-precipitated NPM-MLF1 fusion protein. As seen in Figure 1a , a protein of approximately 56 kDa corresponding to the FLAG-tagged fusion protein was detected in the total cell lysate (lane 3) and in the precipitated NPM complex (lane 6), but not in control cell lysates. The physical interaction between NPM-MLF1 and endogenous NPM was further confirmed using an anti-FLAG antibody to precipitate the NPM-MLF1 protein, followed by immunoblotting with the anti-NPM antibody. The 40-kDa NPM protein was detected in the NPM-MLF1 immunoprecipitates (lane 6, Figure 1b ). As high levels of NPM protein were still present following immunodepletion with the FLAG antibody, this suggests that only a proportion of endogenous NPM interacts with NPM-MLF1 (lanes 10 --12). Hence, it is possible that the effect of NPM-MLF1 may be masked by relatively high-abundance NPM in normal HPCs, suggesting a crucial role of NPM haploinsufficiency in NPM-MLF1-associated pathogenesis. As shown, NPM-MLF1 physically interacts with the endogenous NPM protein. We hypothesized that the reduced level of wild-type NPM, due to the loss of one functional allele of the NPM1 gene during the balanced translocation that forms the NPM-MLF1 fusion gene, is a critical step in the initiation of MDS. As human MDS has been thought to arise from haematopoietic stem or progenitor cells, we examined the effects of NPM-MLF1 on cellular proliferation (Figure 2a ) and colony forming ability (Figure 2b ) of murine HPCs. To determine whether Npm gene dosage influences the activity of NPM-MLF1, the fusion was expressed in the Npm þ / þ and Npm þ /À HPCs. HPCs progressively lose their progenitor activity during in vitro liquid cultures, as measured by a reduction of colony-forming ability. We used this assay to examine the effect of NPM-MLF1 on the colony-forming ability of HPCs, with either wild-type or reduced levels of NPM1. HPCs transduced with either the vector control (containing tailess hCD2 reporter) 11 or NPM-MLF1-expressing retroviral vector were placed in liquid culture. As shown in Figure 2a , the proliferation rate was comparable between the Npm þ / þ and Npm þ /À HPCs liquid cultures, regardless of NPM-MLF1 expression. Therefore, neither expression of NPM-MLF1 nor Npm haploinsufficiency impacts on the growth rate of the cells. These cells were maintained in liquid culture and their colonyforming ability examined at various time points (Figure 2b ). At 5 days post transduction, numbers of colonies generated by NPM-MLF1-expressing Npm þ /À HPCs were similar to the vector control. At day 16 post transduction, numbers of colonies generated by NPM-MLF1-expressing Npm þ /À cells were significantly greater than the control and wild-type cultures, in both the first and second rounds of plating. Although there was no difference in the colony morphology between the cultures, NPM-MLF1-expressing Npm þ /À cells harvested from the first round cells did not form colonies after the second round of plating. At day 28, the colony-forming capacity of NPM-MLF1 Npm þ /À cells was reduced as compared with day 16, but was still increased over the control cultures. Collectively, our data suggest an enhanced progenitor activity promoted by NPM-MLF1 in the background of Npm haploinsufficiency. To examine whether prolonged colony formation correlated with expression of genes known to be involved in myeloid progenitor activity, we analyzed gene expression of HoxA9, HoxA10, Meis1 during the liquid culture using quantitative real-time PCR. As shown in Figure 2c , at day 5 post-transduction, expression levels of Hoxa9/10 and Meis1 genes were similar between wild-type and Npm HPCs transduced with NPM-MLF1, but not in the other three cultures. Interestingly, Meis1 expression levels were slightly increased in the NPM-MLF1-expressing Npm þ /À HPCs from day 5 to day 28, whereas it decreased in the other three cultures. Taken together, our data show that expression of NPM-MLF1 prolongs expression of Hoxa9/10 and Meis1 genes in the Npm haploinsufficient background, most likely due to extended maintenance of immature cells in these cultures. Nevertheless, NPM-MLF1-expressing Npm þ /À HPCs lost their replating ability eventually, suggesting acquisition of secondary mutations might be required in transformation of these HPCs. To address the transforming ability of NPM-MLF1 in vivo, we performed bone marrow transplantation. Npm þ /À bone marrow cells transduced with NPM-MLF1-expressing viruses were transplanted into lethally irradiated C57BL/6 mice. However, we failed to detect any leukemia in recipient mice in a 12-month follow-up period.
These data reveal the potential impact of NPM-MLF1 on HPC activity in MDS/AML patients that concurs with the findings reported in a recent study demonstrating that NPM-MLF1 induced long-term expansion of mouse bone marrow colonies. 12 However, our study extends these data by demonstrating that in addition to the expression of NPM-MLF1 fusion, loss of wild-type NPM is crucial to the activity of the fusion in haematopoietic cells and likely to disease development. Human NPM-MLF1 þ AML cells, in addition to losing one copy of wild-type NPM, also exhibit dislocation of the remaining NPM protein from the nucleolus, its physiological site of action, to the cytoplasm. 13 The cytoplasmic NPMc þ mutation is associated with up to one-third of adult AML and its transgenic expression results in myeloproliferation.
14 This indicates that cytoplasmic expression of NPM results in myeloid transformation. Interestingly, the relative expression levels of NPM and NPMc þ have been shown to influence the balance between nuclear and cytoplasmic localization of both proteins. 15 We show that endogenous NPM can physically interact with the NPM-MLF1 fusion protein, probably via the NPM portion of the fusion. Furthermore, in human NPM-MLF1 þ AML the fusion is found to accumulate in cytoplasm. 13 Thus, it is possible that changes in the subcellular localization of NPM, due to alterations in the relative abundance of NPM and NPM-MLF1 proteins, may contribute to the enhanced myeloid progenitor activity of Npm þ /À HPCs expressing the NPM-MLF1 fusion.
